Annovis Bio, Inc. (NYSE:ANVS) Receives Average Rating of “Buy” from Analysts

Annovis Bio, Inc. (NYSE:ANVS) has been assigned a consensus recommendation of “Buy” from the six brokerages that are covering the firm, MarketBeat reports. One analyst has rated the stock with a hold recommendation, four have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $37.00.

Separately, D. Boral Capital reaffirmed a “hold” rating on shares of Annovis Bio in a research report on Monday, February 10th.

Annovis Bio Stock Performance

Shares of ANVS stock opened at $1.60 on Thursday. The company has a market capitalization of $22.78 million, a P/E ratio of -0.36 and a beta of 1.65. Annovis Bio has a 52 week low of $1.43 and a 52 week high of $20.00. The company’s 50 day moving average price is $2.47 and its two-hundred day moving average price is $5.38.

Annovis Bio (NYSE:ANVS) last issued its quarterly earnings data on Friday, March 21st. The company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). During the same period last year, the business posted ($0.43) EPS. Analysts forecast that Annovis Bio will post -2.19 earnings per share for the current year.

Institutional Investors Weigh In On Annovis Bio

Several institutional investors and hedge funds have recently added to or reduced their stakes in ANVS. Two Sigma Investments LP acquired a new stake in shares of Annovis Bio in the fourth quarter valued at about $55,000. Cubist Systematic Strategies LLC acquired a new position in shares of Annovis Bio during the 4th quarter worth approximately $258,000. Jane Street Group LLC raised its stake in shares of Annovis Bio by 99.7% during the 4th quarter. Jane Street Group LLC now owns 68,107 shares of the company’s stock worth $343,000 after purchasing an additional 34,001 shares in the last quarter. Northern Trust Corp boosted its holdings in shares of Annovis Bio by 49.4% in the 4th quarter. Northern Trust Corp now owns 32,780 shares of the company’s stock valued at $165,000 after buying an additional 10,846 shares during the last quarter. Finally, XTX Topco Ltd bought a new position in shares of Annovis Bio in the fourth quarter valued at $59,000. 15.83% of the stock is owned by institutional investors.

About Annovis Bio

Annovis Bio, Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases.